Literature DB >> 1318170

The role of deoxycytidine-metabolizing enzymes in the cytotoxicity induced by 3'-amino-2',3'-dideoxycytidine and cytosine arabinoside.

W R Mancini1.   

Abstract

The cellular metabolism of 3'-amino-2',3'-dideoxycytidine (3'-NH2-dCyd), a cytotoxic agent previously reported to be a poor substrate for purified Cyd/dCyd deaminase (dCydD), was compared with that of cytosine arabinoside (ara-C) in cells that displayed dCydD activity (HeLa) and in cells that did not (L1210). Growth inhibition induced by 3'-NH2-dCyd was dependent on the levels of anabolic enzymes, particularly dCyd kinase (dCydK), whereas cytotoxicity induced by ara-C was dependent on the expression of both anabolic and catabolic enzyme activities. Competition kinetics using purified enzyme revealed that the binding affinity of ara-C to dCydK was 5-fold that of the amino analog. However, this binding advantage is apparently offset in cells that contain high levels of dCydD, since the Ki values for this enzyme were 0.2 and 23 mM for ara-C and 3'-NH2-dCyd, respectively. This was reflected in the decrease in analog sensitivity observed between the two cell lines, whereby the concentrations of ara-C and 3'-NH2-dCyd required to inhibit growth by 50% were 200 and 7 times higher, respectively, in the dCydD-containing HeLa cells as compared with the dCydD-deficient L1210 cells. The metabolic stability and cytotoxicity of 3'-NH2-dCyd was independent of cell number. An unexpected finding was the extent to which the effectiveness of ara-C could be mitigated by the number of dCydD-containing cells. A completely cytotoxic concentration of ara-C was rendered nontoxic by a 10-fold increase in cell number. This observation was supported by an increase in I-beta-D-arabinofuranosyluracil (ara-U) formation, a decrease in ara-C 5'-triphosphate (ara-CTP) accumulation, and a rise in cell viability with increasing cell number. These findings indicate that unlike ara-C, the effectiveness of 3'-NH2-dCyd is independent of the level of deaminase, which suggests its possible utility in situations in which high levels of deaminase are manifest.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1318170     DOI: 10.1007/bf00686406

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  27 in total

1.  Statistical analysis of radioligand assay data.

Authors:  D Rodbard; G R Frazier
Journal:  Methods Enzymol       Date:  1975       Impact factor: 1.600

2.  Purification and properties of cytidine deaminase from normal and leukemic granulocytes.

Authors:  B A Chabner; D G Johns; C N Coleman; J C Drake; W H Evans
Journal:  J Clin Invest       Date:  1974-03       Impact factor: 14.808

3.  Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity.

Authors:  G W Camiener; C G Smith
Journal:  Biochem Pharmacol       Date:  1965-10       Impact factor: 5.858

4.  Plasma half-life of cytosine arabinoside (NSC-63878) in patients treated for acute myeloblastic leukemia.

Authors:  B C Baguley; E M Falkenhaug
Journal:  Cancer Chemother Rep       Date:  1971-06

5.  Cytidine deaminase and the development of resistance to arabinosyl cytosine.

Authors:  C D Steuart; P J Burke
Journal:  Nat New Biol       Date:  1971-09-22

6.  Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and response to therapy.

Authors:  Y M Rustum; H D Preisler
Journal:  Cancer Res       Date:  1979-01       Impact factor: 12.701

7.  Specific inhibition of DNA biosynthesis induced by 3'-amino-2',3'-dideoxycytidine.

Authors:  W R Mancini; M S Williams; T S Lin
Journal:  Biochemistry       Date:  1988-11-29       Impact factor: 3.162

8.  Ribo- and deoxyribonucleoside effect on 3'-amino-2',3'-dideoxycytidine-induced cytotoxicity in cultured L1210 cells.

Authors:  W R Mancini; T S Lin
Journal:  Biochem Pharmacol       Date:  1983-08-15       Impact factor: 5.858

9.  Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.

Authors:  V I Avramis; R Biener; M Krailo; J Finklestein; L Ettinger; M Willoughby; S E Siegel; J S Holcenberg
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

10.  Tetrahydrouridine: Physiologic disposition and effect upon deamination of cytosine arabinoside in man.

Authors:  W Kreis; T M Woodcock; C S Gordon; I H Krakoff
Journal:  Cancer Treat Rep       Date:  1977-10
View more
  1 in total

1.  Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study.

Authors:  R A Fleming; R L Capizzi; G L Rosner; L K Oliver; S J Smith; C A Schiffer; R T Silver; B A Peterson; R B Weiss; G A Omura
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.